EA201790070A1 - Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 - Google Patents
Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70Info
- Publication number
- EA201790070A1 EA201790070A1 EA201790070A EA201790070A EA201790070A1 EA 201790070 A1 EA201790070 A1 EA 201790070A1 EA 201790070 A EA201790070 A EA 201790070A EA 201790070 A EA201790070 A EA 201790070A EA 201790070 A1 EA201790070 A1 EA 201790070A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biphenylamide
- hsp70
- stimulators
- ether groups
- containing modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
В настоящем изобретении предложены соединения формулыгде n, Х, R, R,R, R,R, R,Rи Rтакие, как определено в настоящем описании. Также предложены фармацевтические композиции, содержащие соединения. Согласно некоторым аспектам указанные соединения можно применять для лечения заболеваний, включая диабетическую периферическую нейропатию или рак.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462016473P | 2014-06-24 | 2014-06-24 | |
PCT/US2015/037478 WO2015200514A2 (en) | 2014-06-24 | 2015-06-24 | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790070A1 true EA201790070A1 (ru) | 2017-10-31 |
Family
ID=53525293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790070A EA201790070A1 (ru) | 2014-06-24 | 2015-06-24 | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 |
Country Status (15)
Country | Link |
---|---|
US (3) | US10590065B2 (ru) |
EP (1) | EP3160977A2 (ru) |
JP (2) | JP6793640B2 (ru) |
KR (1) | KR102536408B1 (ru) |
CN (1) | CN106536498A (ru) |
AU (2) | AU2015279926B2 (ru) |
CA (1) | CA2952029A1 (ru) |
CL (2) | CL2016003276A1 (ru) |
CO (1) | CO2017000552A2 (ru) |
EA (1) | EA201790070A1 (ru) |
IL (1) | IL249712B (ru) |
MX (2) | MX2016017133A (ru) |
NZ (1) | NZ728482A (ru) |
SG (2) | SG10201811574YA (ru) |
WO (1) | WO2015200514A2 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9422320B2 (en) | 2012-02-09 | 2016-08-23 | University Of Kansas | C-terminal HSP90 inhibitors |
EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
WO2015200514A2 (en) | 2014-06-24 | 2015-12-30 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
CN108478568B (zh) * | 2018-02-01 | 2020-08-28 | 华中农业大学 | 一种香豆素类化合物在制备单胺氧化酶抑制剂中的用途 |
TW202323267A (zh) * | 2018-02-07 | 2023-06-16 | 美商瑞塔醫藥有限責任公司 | 新生黴素(novobiocin)類似物及脯胺酸之共晶型及其用途 |
IL309891A (en) * | 2018-05-14 | 2024-03-01 | Reata Pharmaceuticals Inc | Bi-aryl amides with sugar groups that are adapted to the treatment of related diseases |
KR102175125B1 (ko) * | 2018-12-28 | 2020-11-05 | 울산과학기술원 | 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
EP1807440B1 (en) | 2004-11-03 | 2020-02-19 | The University of Kansas | Novobiocin analogues as anticancer agents |
WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
EP2131656A4 (en) | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
MX2009009936A (es) | 2007-03-20 | 2010-02-11 | Curis Inc | Amino piridina fusionada como inhibidores de hsp90. |
US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
WO2011041593A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
JP5961683B2 (ja) * | 2011-04-05 | 2016-08-02 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90阻害物質 |
US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
WO2012163054A1 (zh) | 2011-11-16 | 2012-12-06 | 华为技术有限公司 | 一种微波预失真信号生成方法和装置 |
US9422320B2 (en) | 2012-02-09 | 2016-08-23 | University Of Kansas | C-terminal HSP90 inhibitors |
WO2015200514A2 (en) | 2014-06-24 | 2015-12-30 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
-
2015
- 2015-06-24 WO PCT/US2015/037478 patent/WO2015200514A2/en active Application Filing
- 2015-06-24 AU AU2015279926A patent/AU2015279926B2/en active Active
- 2015-06-24 SG SG10201811574YA patent/SG10201811574YA/en unknown
- 2015-06-24 SG SG11201610677XA patent/SG11201610677XA/en unknown
- 2015-06-24 JP JP2017520743A patent/JP6793640B2/ja active Active
- 2015-06-24 NZ NZ728482A patent/NZ728482A/en unknown
- 2015-06-24 KR KR1020177001978A patent/KR102536408B1/ko active IP Right Grant
- 2015-06-24 US US15/321,289 patent/US10590065B2/en active Active
- 2015-06-24 EA EA201790070A patent/EA201790070A1/ru unknown
- 2015-06-24 EP EP15735815.1A patent/EP3160977A2/en active Pending
- 2015-06-24 MX MX2016017133A patent/MX2016017133A/es unknown
- 2015-06-24 CN CN201580033560.XA patent/CN106536498A/zh active Pending
- 2015-06-24 CA CA2952029A patent/CA2952029A1/en active Pending
-
2016
- 2016-12-19 MX MX2019015888A patent/MX2019015888A/es unknown
- 2016-12-21 CL CL2016003276A patent/CL2016003276A1/es unknown
- 2016-12-22 IL IL249712A patent/IL249712B/en active IP Right Grant
-
2017
- 2017-01-23 CO CONC2017/0000552A patent/CO2017000552A2/es unknown
-
2018
- 2018-08-17 CL CL2018002367A patent/CL2018002367A1/es unknown
-
2020
- 2020-01-29 US US16/776,091 patent/US11098008B2/en active Active
- 2020-11-10 JP JP2020186914A patent/JP7105851B2/ja active Active
-
2021
- 2021-02-15 AU AU2021200969A patent/AU2021200969B2/en active Active
- 2021-07-14 US US17/375,882 patent/US11708319B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180057446A1 (en) | 2018-03-01 |
US10590065B2 (en) | 2020-03-17 |
EP3160977A2 (en) | 2017-05-03 |
KR20170035911A (ko) | 2017-03-31 |
US11098008B2 (en) | 2021-08-24 |
SG11201610677XA (en) | 2017-01-27 |
KR102536408B1 (ko) | 2023-05-23 |
MX2019015888A (es) | 2020-02-07 |
CL2016003276A1 (es) | 2017-05-26 |
CL2018002367A1 (es) | 2018-10-12 |
AU2015279926A1 (en) | 2017-02-16 |
WO2015200514A2 (en) | 2015-12-30 |
MX2016017133A (es) | 2018-01-12 |
JP7105851B2 (ja) | 2022-07-25 |
CA2952029A1 (en) | 2015-12-30 |
JP2021042217A (ja) | 2021-03-18 |
AU2021200969B2 (en) | 2022-08-04 |
JP2017521496A (ja) | 2017-08-03 |
AU2021200969A1 (en) | 2021-03-11 |
SG10201811574YA (en) | 2019-01-30 |
AU2015279926B2 (en) | 2020-12-24 |
BR112016029672A2 (pt) | 2017-08-22 |
CO2017000552A2 (es) | 2017-04-28 |
US11708319B2 (en) | 2023-07-25 |
IL249712A0 (en) | 2017-02-28 |
US20200270201A1 (en) | 2020-08-27 |
NZ728482A (en) | 2022-11-25 |
IL249712B (en) | 2021-04-29 |
WO2015200514A3 (en) | 2016-02-25 |
CN106536498A (zh) | 2017-03-22 |
US20220041543A1 (en) | 2022-02-10 |
JP6793640B2 (ja) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
EA201691940A1 (ru) | Новые соединения | |
EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. |